ArticleVaccine2010
Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.
Article in Vaccine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- BRAF Inhibition and UVB Light Synergistically PromoteCancers · 2024Article
- Determination of Causative Human Papillomavirus Type in Tissue Specimens of Common Warts Based on Estimated Viral Loads.Frontiers in cellular and infection microbiology · 2020Article
- Opportunities and challenges for human papillomavirus vaccination in cancer.Nature reviews. Cancer · 2018Review
- Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?Frontiers in microbiology · 2018Review
- Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).PloS one · 2017Article
- Design strategies to address the effect of hydrophobic epitope on stability and in vitro assembly of modular virus-like particle.Protein science : a publication of the Protein Society · 2016Article
- Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner.PloS one · 2015Article
- HPV vaccination for prevention of skin cancer.Human vaccines & immunotherapeutics · 2015Review
- Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.BMC microbiology · 2014Article
- Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.PloS one · 2014Article
- Evaluation of a novel multiplex human papillomavirus (HPV) genotyping assay for HPV types in skin warts.Journal of clinical microbiology · 2011Article
- [Clinical algorithm of cutaneous extragenital wart treatment].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The potential as prophylactic vaccines of L1-based particles from cutaneous genus alpha human papillomavirus (HPV) types has not been assessed so far. However, there is a high medical need for such vaccines since HPV-induced skin warts represent a major burden for children and for immunocompromised adults, such as organ transplant recipients. In this study, we have examined the immunogenicity of capsomeres and virus-like particles (VLPs) from HPV types 2, 27, and 57, the most frequent causative agents of skin warts. Immunization of mice induced immune responses resembling those observed upon vaccination with HPV 16 L1-based antigens. The antibody responses were cross-reactive but type-restricted in their neutralizing capacities. Application of adjuvant led to an enhanced potential to neutralize the respective immunogen type but did not improve cross-neutralization. Vaccination with capsomeres and VLPs from all four analyzed HPV types induced robust IFNgamma-associated T-cell activation. Immunization with mixed VLPs from HPV types 2, 27, and 57 triggered an antibody response similar to that after single-type immunization and capable of efficiently neutralizing all three types. Our results imply that vaccination with combinations of VLPs from cutaneous HPV types constitutes a promising strategy to prevent HPV-induced skin lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.